288 Treatment of advanced breast cancer by medroxyprogesterone acetate (MPA). results of a French multi-center trial

Gorins, A; Marty, M.; Mignot, L.; Gisselbrecht, C; Belpomme, D; Espié, Marc; Morvan, F.; Juret, P; Namer, M.

doi:10.1016/0022-4731(83)91788-0

Journal of Steroid Biochemistry

1983

DOI: 10.1016/0022-4731(83)91788-0

|View full text |Cite

288 Treatment of advanced breast cancer by medroxyprogesterone acetate (MPA). results of a French multi-center trial

A Gorins¹,

M. Marty²,

L. Mignot³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1985

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another therapeutic possibility is medroxyprogesterone acetate (MPA), a synthetic progesterone which has been used as an anovulatory agent because of its blocking effect on gonadotropin secretion. High dose MPA is also used in the treatment of breast cancer (Gorins et al, 1983). Inhibition of LH secretion (Gordon, Southren & Tochimoto, 1970), with subsequent reduced T production and increased metabolic clearance rate of testosterone (Altmann et al, 1972;Gordon et al, 1972), results in a decrease of androgen serum levels.…”

mentioning

confidence: 99%

Medroxyprogesterone acetate therapy in hirsutism

1985

View full text Add to dashboard Cite

In a pilot study, 26 hirsute females were treated with medroxyprogesterone acetate (MPA). We used an ointment containing 0.2% MPA in 13 patients, subcutaneous injection of MPA into the hairy areas of the face in five patients and intramuscular injection of low doses of MPA in 13 patients, each for an average duration of 16 weeks. The best clinical result was achieved by subcutaneous injection, the next most successful was the intramuscular injection, and the least successful was the topical application. Hair diameter measurements, carried out in 12 patients, were found to be reduced by 33% on average. Serum androgen levels, measured monthly, remained unaffected by topical treatment, but were decreased by intralesional and intramuscular injection. The clinical improvement with topical therapy despite the lack of effect on serum androgen levels supports the idea that MPA works partly at the cellular level. The intralesional and systemic injection of MPA may exert an effect both by systemic androgen suppression and a local action.

show abstract

mentioning

confidence: 99%

Medroxyprogesterone acetate therapy in hirsutism

1985

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

288 Treatment of advanced breast cancer by medroxyprogesterone acetate (MPA). results of a French multi-center trial

Cited by 1 publication

References 0 publications

Medroxyprogesterone acetate therapy in hirsutism

Medroxyprogesterone acetate therapy in hirsutism

Contact Info

Product

Resources

About